31602-11-6Relevant articles and documents
Synthetic method of 8-(trifluoromethyl)quinoline-3-carboxylate
-
, (2018/09/11)
The invention provides a synthetic method of 8-(trifluoromethyl)quinoline-3-carboxylate. The synthetic method comprises the following steps: reacting 2-(trifluoromethyl)aniline serving as a starting raw material to obtain 8-(trifluoromethyl)quinoline-3-ethyl ester carboxylate; lastly, hydrolyzing the 8-(trifluoromethyl)quinoline-3-ethyl ester carboxylate in an alkaline environment to obtain 8-(trifluoromethyl)quinoline-3-carboxylate. According to the synthetic method of the 8-(trifluoromethyl)quinoline-3-carboxylate provided by the invention, a synthetic route taking 2-(trifluoromethyl)anilineas a raw material is provided. The synthetic method has the advantages of simple synthetic route, reasonable process selection, low raw material cost, adoption of simple and readily-available raw materials, convenience in operation and post-treatment, high total yield, no use of any highly-toxic reagent, easiness in amplification, realization of large-scale production and the like.
Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antimycobacterial agents
Eswaran, Sumesh,Adhikari, Airody Vasudeva,Pal, Nishith K.,Chowdhury, Imran H.
supporting information; experimental part, p. 1040 - 1044 (2010/06/14)
A series of 26 new quinoline derivatives carrying active pharmacophores has been synthesized and evaluated for their in vitro antituberculosis activity against Mycobacterium tuberculosis H37Rv (MTB), Mycobacterium smegmatis (MC2), and Mycobacterium fortuitum following the broth micro dilution assay method. Compounds 13e, 13i, 13k, 14a, 14c, 14i, and 14k exhibited significant minimum inhibition concentrations, when compared with first line drugs isoniazid (INH) and rifampicin (RIF) and could be ideally suited for further modifications to obtain more efficacious compounds in the fight against multi-drug resistant tuberculosis.
Quinolines useful in treating cardiovascular disease
-
Page/Page column 28, (2008/06/13)
This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.